|
The sensitivity, specificity, positive (PPV) and negative predictive values (NPV) of WHO clinical stage and plasma viral load against CD4 count for the assessment of eligibility to ART. |
||||||
| CD4 count × 106/l (no. of subjects) |
Sensitivity |
Specificity |
PPV |
NPV |
||
|
|
||||||
| All subjects screened |
<200 |
≥ 200 |
Percent (95% CI) |
|||
| WHO clinical stage |
||||||
| III, IV |
1163 |
648 |
52 (50, 54) |
68 (66, 70) |
64 (62, 66) |
56 (54, 58) |
| I, II |
1091 |
1400 |
||||
| <250 |
≥ 250 |
|||||
| III, IV |
1320 |
491 |
52 (50,53) |
72 (70, 74) |
73 (71, 75) |
50 (48, 52) |
| I, II |
1241 |
1250 |
||||
| <350 |
≥ 350 |
|||||
| III, IV |
1515 |
296 |
48 (46–50) |
74 (72–77) |
84 (82–85) |
34 (32–36) |
| I, II |
1640 |
851 |
||||
| Subjects enrolled in the trial |
<200 |
≥ 200 |
||||
| WHO clinical stage |
||||||
| III, IV |
708 |
83 |
54 (51, 56) |
37 (29, 46) |
90 (87, 92) |
7 (6, 10) |
| I, II |
613 |
49 |
||||
| advanced III, IV |
561 |
70 |
42 (40, 45) |
47 (38, 56) |
89 (86, 91) |
8 (6, 10) |
| I, II, early III |
760 |
62 |
||||
| IV |
102 |
17 |
8 (6, 9) |
87 (80, 92) |
86 (78, 91) |
9 (7, 10) |
| I, II, III |
1219 |
115 |
||||
| Plasma RNA viral load, copies per ml Ω |
||||||
| ≥ 100,000 |
878 |
60 |
66 (64, 69) |
55 (46, 63) |
94 (92, 95) |
14 (11, 17) |
| <100,000 |
443 |
72 |
||||
| Plasma viral load, copies per ml tested within 30 days of CD4 test |
||||||
| ≥ 100,000 |
411 |
19 |
66 (62, 70) |
68 (55, 80) |
96 (93, 97) |
16 (12, 22) |
| <100,000 |
209 |
41 |
||||
|
Ω Median (IQR) interval between the CD4 count and plasma viral load tests was 32 (28–45) days. Note: the subjects enrolled in the trial were a subset of all subjects screened. | ||||||
Jaffar et al. AIDS Research and Therapy 2008 5:4 doi:10.1186/1742-6405-5-4 |
||||||